Page 116 - 《中国药房》2025年4期
P. 116

33(5):622-627.                                      分析[J]. 药学实践杂志,2020,38(2):174-178.
               HUANG  C  B,LI  W  P,XU  R  F,et  al.  Reevaluation  of     YAO N N,LIN L L,HUANG S,et al. Analysis of adverse
               systematic  evaluation  of  gemcitabine  combined  with  cis‐  reactions in 312 cases of gemcitabine[J]. J Pharm Pract,
               platin  in  the  treatment  of  advanced  non-small  cell  lung   2020,38(2):174-178.
               cancer[J]. China Pharm,2022,33(5):622-627.     [15]  THARPE  N. Adverse  drug  reactions  in  women’s  health
          [ 5 ]  刘卫平,谌武兵.吉西他滨联合顺铂治疗晚期NSCLC的                        care[J]. J Midwifery Womens Health,2011,56(3):205-213.
               临床疗效及安全性[J].临床合理用药,2024,17(12):9-12.           [16]  左成淳,许青,李晓宇,等 . 替加环素肝功能异常风险的
               LIU W P,SHEN W B.Clinical efficacy and safety of gem‐  回顾性观察研究[J]. 中国医院药学杂志,2024,44(18):
               citabine  combined  with  cisplatin  in  the  treatment  of         2146-2153.
               advanced NSCLC[J].Chin J Clin Rat Drug Use,2024,17  ZUO  C  C,XU  Q,LI  X  Y,et  al. Risk  of  liver  function
              (12):9-12.                                           abnormalities with tigecycline:a retrospective observational
          [ 6 ]  BAYRAM  E,TOYRAN  T,PAYDAS  S.  Gemcitabine-      study[J]. Chin J Hosp Pharm,2024,44(18):2146-2153.
               associated  DRESS  syndrome:a  case  report[J].  J  Oncol   [17]  CASTBERG  I,WESTIN  A  A,SKOGVOLL  E,et  al.
               Pharm Pract,2023,29(6):1480-1483.                   Effects of age and gender on the serum levels of clozapine,
          [ 7 ]  CTCAE  V5.0. Common  terminology  criteria  for  adverse   olanzapine,risperidone,and quetiapine[J]. Acta Psychiatr
               events (CTCAE)  version  5.0.  2017. [EB/OL].(2021-06-  Scand,2017,136(5):455-464.
               28)[2024-09-25]. https://ctep.cancer.gov/protocoldevelop‐  [18]  MANTEUFFEL  M,WILLIAMS  S,CHEN  W,et  al.
               ment/electronic_applications/docs/CTCAE_V5_Quick_Re-  Influence  of  patient  sex  and  gender  on  medication  use,
               ference_8.5x11.pdf.                                 adherence,and prescribing alignment with guidelines[J]. J
          [ 8 ]  李伯妍,郭代红,孔祥豪,等 . 972 例抗肿瘤血管生成类                     Womens Health (Larchmt),2014,23(2):112-119.
               药品不良反应自发报告分析[J]. 中国临床药理学杂志,                    [19]  羊波,孙云峰,郑造乾,等. 超说明书用药法律释读及应
               2021,37(11):1441-1443,1450.                         对策略分析[J]. 中国现代应用药学,2019,36(8):993-996.
               LI  B Y,GUO  D  H,KONG  X  H,et  al. Analysis  of  972   YANG B,SUN Y F,ZHENG Z Q,et al. Legal interpreta‐
               spontaneous reports of adverse drug reactions induced by   tion and coping strategy analysis on off-label use[J]. Chin
               angiogenesis inhibitors[J]. Chin J Clin Pharmacol,2021,  J Mod Appl Pharm,2019,36(8):993-996.
               37(11):1441-1443,1450.                         [20]  国家卫生健康委办公厅 . 膀胱癌诊疗指南:2022 年版
          [ 9 ]  邱爽,崔向丽,王颖 . 112 例吉西他滨不良反应分析[J].                   [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
               中国新药杂志,2014,23(17):2085-2088.                       cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
               QIU S,CUI X L,WANG Y. Analysis of 112 patients with   7c74/files/7224e506d4a24b90a9df0424888ba38a.pdf.
               adverse drug reactions induced by gemcitabine[J]. Chin J   Office of the National Health Commission. Guidelines for
               N Drugs,2014,23(17):2085-2088.                      diagnosis  and  treatment  of  bladder  cancer:2022  edition
          [10]  马颖林,乐凯迪,闫加庆,等 . 真实世界阿帕替尼治疗乳                        [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
               腺癌的不良反应及危险因素分析[J]. 中国药学杂志,                          cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
               2022,57(4):310-314.                                 7c74/files/7224e506d4a24b90a9df0424888ba38a.pdf.
               MA Y L,LE K D,YAN J Q ,et al.Analysis of the adverse   [21]  国家卫生健康委办公厅 . 卵巢癌诊疗指南:2022 年版
               reactions  and  risk  factors  of  apatinib  in  the  treatment  of   [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
               breast cancer in real world[J].Chin Pharmaceut J,2022,57  cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
              (4):310-314.                                         7c74/files/0feefc11d98840898b136ac3d9a4ee20.pdf.
          [11]  WANG  Y,HU  G  F,ZHANG  Q  Q,et  al.  Efficacy  and   Office of the National Health Commission. Guidelines for
               safety  of  gemcitabine  plus  erlotinib  for  locally  advanced   diagnosis  and  treatment  of  ovarian  cancer:2022  edition
               or  metastatic  pancreatic  cancer:a  systematic  review  and   [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
               meta-analysis[J].Drug Des Devel Ther,2016,10:1961-1972.  cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
          [12]  黄彦珊 . 2017-2020 年某院铂类药物不良反应分析[J].                  7c74/files/0feefc11d98840898b136ac3d9a4ee20.pdf.
               中国处方药,2023,21(2):90-93.                        [22]  汪龙,朱玲娜,宋佳伟,等. 吉西他滨合理应用评价标准
               HUANG Y S. Analysis of the adverse reactions of plati‐  的建立及应用[J]. 中国新药与临床杂志,2020,39(9):
               num drugs in our hospital from 2017 to 2020[J]. J China   568-574.
               Prescr Drug,2023,21(2):90-93.                       WANG L,ZHU L N,SONG J W,et al. Establishment and
          [13]  马力,时俊锋,童宁 . 紫杉醇类药物的不良反应研究[J].                      application of evaluation criteria for rational use of gem‐
               中国药房,2018,29(21):3014-3017.                         citabine[J]. Chin J N Drugs Clin Remedies,2020,39(9):
               MA L,SHI J F,TONG N. Study on adverse reactions of   568-574.
               taxol drugs[J]. China Pharm,2018,29(21):3014-3017.           (收稿日期:2024-09-07  修回日期:2024-11-27)
          [14]  姚囡囡,林莉莉,黄珊,等 . 312 例吉西他滨的不良反应                                                     (编辑:舒安琴)



          · 490 ·    China Pharmacy  2025 Vol. 36  No. 4                               中国药房  2025年第36卷第4期
   111   112   113   114   115   116   117   118   119   120   121